As with the CTL4 brake, disabling PD - 1 can have dramatic effects against melanoma and several other types of cancer, but again, the response is far from universal.
Hodi designed this investigator - initiated clinical trial to find out if giving sargramostim along with ipilimumab would have a synergistic effect against the melanoma — like pressing the immune system's accelerator while releasing the brake.